Valuation: CorMedix Inc.

Market Cap 637M 546M 510M 468M 880M 60.87B 895M 6.02B 2.36B 30.53B 2.39B 2.34B 101B P/E 2026 *
16.7x
P/E 2027 * 136x
Enterprise Value 637M 546M 510M 468M 880M 60.87B 895M 6.02B 2.36B 30.53B 2.39B 2.34B 101B EV / Sales 2026 *
1.89x
EV / Sales 2027 * 2.22x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day+4.28%
1 week+16.71%
Current month+13.15%
1 month+1.19%
3 months+7.71%
6 months+18.83%
Current year-26.74%
1 week 7.46
Extreme 7.46
8.98
1 month 7.1
Extreme 7.1
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap.
2/4/26 A Free

Chief Executive Officer

77,156 0.0979%
2/4/26 A Free

General Counsel

36,006 0.0457%
2/4/26 A Free

Chief Operating Officer

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
+4.28%+16.71%-34.96%+108.31% 637M
+12.60%+16.70%+80.72%+39.38% 333B
+1.17%-1.18%+24.92%-13.01% 68.84B
+2.60%+4.87%+56.06%+148.77% 11.9B
+0.99%+1.05%-1.61%+0.90% 8.41B
+0.12%-5.75%-14.01%-1.39% 4.72B
0.00%-7.01%-29.99%+14.02% 4.2B
-8.17%-24.88%-25.84%+13.46% 3.48B
-1.00%+3.54%+12.91%+56.73% 2.85B
-2.79%-6.85%-9.11%-6.03% 2.19B
Average +1.07%-1.74%+5.91%+36.11% 44.07B
Weighted average by Cap. +10.19%+2.20%+65.80%+32.52%

Financials

2026 *2027 *
Net sales 337M 289M 270M 248M 466M 32.22B 474M 3.19B 1.25B 16.16B 1.27B 1.24B 53.43B 286M 246M 229M 211M 396M 27.38B 402M 2.71B 1.06B 13.73B 1.08B 1.05B 45.4B
Net income 45.66M 39.17M 36.57M 33.56M 63.1M 4.36B 64.14M 432M 169M 2.19B 171M 168M 7.24B 5.69M 4.88M 4.55M 4.18M 7.86M 543M 7.99M 53.74M 21.04M 273M 21.35M 20.88M 901M
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
19/08/26 $8.520 +4.28% 1,465,138
18/08/26 $8.170 +6.52% 2,033,422
17/08/26 $7.670 +1.72% 2,173,712
14/08/26 $7.540 -7.37% 2,701,417
13/08/26 $8.140 +14.65% 6,069,943
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.170USD
Average target price
15.40USD
Spread / Average Target
+88.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock